Introduction

Perampanel (trade name: Fycompa) has been approved in Germany since July 2012 as an add-on therapy for treating epileptic seizures in adults and children over the age of 12.

Epileptic seizures are triggered by abnormal activity in the nerve cells of the brain. Epileptic seizures can cause reduced consciousness, altered awareness, and muscle twitching, as well as severe cramps and discomfort. A seizure usually lasts between a few seconds and a few minutes.

Epileptic seizures are classified as either partial or generalized, depending on how far-reaching they are. Generalized seizures affect the entire body. Partial (or focal) seizures only affect a small part of the brain, with muscle twitching and cramps only occurring in certain parts of the body. Partial seizures can however spread across the whole body – this is called a “secondary generalization.” Perampanel is approved for the treatment of partial seizures with or without secondary generalization in people aged 12 years and over.

Application

Perampanel is used in addition to standard treatment. The drug is taken once a day in tablet form before going to bed. An individual dose will be prescribed at the start of treatment.

Other treatments

There are a number of add-on therapy options that can be used to treat focal seizures depending on the individual circumstances. These drugs include pregabalin, valproic acid, levetiracetam and gabapentin.

Assessment

In 2014, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) last assessed what benefits perampanel has compared with other treatments that may be an option in individual cases.

However, no data on how perampanel compares with other suitable drugs was available to IQWiG.

More information

This text summarizes the most important results of two reviews produced by the Institute for Quality and Efficiency in Health Care (IQWiG, Germany). The reviews were commissioned by the German Federal Joint Committee (G-BA) as part of the "early benefit assessment of medications." On the basis of the reviews and the hearings received, the G-BA passed a resolution on the added benefits of perampanel (Fycompa).

What would you like to share with us?

We welcome any feedback and ideas. We will review, but not publish, your ratings and comments. Your information will of course be treated confidentially. Fields marked with an asterisk (*) are required fields.

Please note that we do not provide individual advice on matters of health. You can read about where to find help and support in Germany in our information “How can I find self-help groups and information centers?”

Recommend this article

You can permanently activate a button here. Please read our privacy policy.